CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
March 21st 2023
Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.
March 17th 2023
From Robin Roberts providing an update on her partner, Amber Laign’s “rough year” with breast cancer, to Kathy Griffin’s suspected cause of lung cancer, here’s what’s happening in the oncology space this week.
March 11th 2023
Patients with resectable non-small cell lung cancer treated with Imfinzi plus chemo before surgery or as monotherapy after surgery demonstrated significant improvements to event-free survival compared with those treated with neoadjuvant chemotherapy and surgery, study results show.
March 9th 2023
Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.
March 3rd 2023
Gefitinib plus chemotherapy could be considered a first-line treatment option for patients with EGFR-mutated NSCLC with brain metastases.
March 1st 2023
The first patient was enrolled in a three-drug clinical trial, which researchers hope will lend insight into immunotherapy resistance in lung cancer.
One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.
February 24th 2023
As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about networking during a lung cancer diagnosis.
As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about supportive services for lung cancer.
As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about what biomarker testing is and why patients with lung cancer should advocate for themselves during that process.
As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about the importance of second opinions during a lung cancer diagnosis.
I’m in the race of cancer, hoping that a cure will pass the finish line before I do.
February 20th 2023
Chemotherapy affected my brain in ways that I was never told about.
February 9th 2023
Some patients with metastatic non-small cell lung cancer are not receiving effective therapies for their disease, the study authors suggested.
February 8th 2023
An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.
February 7th 2023
Postmenopausal women cancer survivors, including lung, breast, colorectal and endometrial cancer, may have a greater physical function decline than is generally expected at their age, which may lead to lower quality of life after treatment.
February 2nd 2023
Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.
January 31st 2023
A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.
January 27th 2023
VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.
January 26th 2023
The Food and Drug Administration approved Keytruda, an immunotherapy agent, for patients with stage 1B, 2 or 3A non-small cell lung cancer.
Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.
January 18th 2023
Patients with operable non-small cell lung cancer who were treated with an anti-PD-1 monoclonal antibody plus a doublet chemotherapy regiment did not experience cancer recurrence or new symptom onset during follow-up in a recent study.
The COVALENT-102 trial will investigate BMF-219 in patients with non-small cell lung cancer, colorectal and pancreatic cancers.
December 29th 2022
Lung cancer survivor Terri Conneran shares her story of creating a non-profit to help connect with fellow patients and survivors who have the KRAS biomarker.
December 21st 2022
An expert explains what the FDA’s accelerated approval of Krazati means for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer and what he hopes will come next.
December 19th 2022
The indication for Pemfexy has been approved to include patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK genomic tumor mutations.
December 15th 2022
In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.
December 13th 2022
Krazati was granted an accelerated approval for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer, according to the Food and Drug Administration.
November 23rd 2022
As part of its “Speaking Out” video series, Dr. Peter Baik, on behalf of Cancer Treatment Centers of America, discussed how far the space has come with surgical advances, and where it is headed, in treating early-stage lung cancer.
As part of its “Speaking Out” video series, Dr. Peter Baik, on behalf of Cancer Treatment Centers of America, discussed the importance of timing and decision-making of treatment in early-stage lung cancer.
Educated Patient® Breast Cancer Summit at MBCC Circulating Tumor DNA Presentation: March 4, 2023
Cancer Overwhelmed Me, But It Didn’t Overtake Me
Educated Patient® Breast Cancer Summit at MBCC Genetic Testing Presentation: March 4, 2023
What I Wish I Knew Before Cancer